Table 1.
Demographic and clinical variables of the subjects.
| FEP | HC | Statistical analysisa | ||
|---|---|---|---|---|
| (n = 40) | (n = 40) | X2 or T | p | |
| Age (years) | 22.88 ± 5.64 | 22.58 ± 3.94 | 0.28 | 0.78 |
| Sex (male/female) | 18/22 | 20/20 | 0.20 | 0.65 |
| Handedness (right/left) | 35/5 | 35/5 | 0 | 1.00 |
| Education (years) | 13.26 ± 2.01 | 14.15 ± 1.83 | − 2.07 | 0.04 |
| IQ | 98.67 ± 13.51 | 111.90 ± 14.68 | − 4.17 | 0.00 |
| Duration of illness (months) | 5.74 ± 3.82 | |||
| Medicationb (mg) | 9.73 ± 7.61 | |||
| PANSS | ||||
| Total | 69.03 ± 14.26 | |||
| Positive symptoms | 16.48 ± 4.86 | |||
| Negative symptoms | 17.45 ± 5.65 | |||
| General symptoms | 35.10 ± 7.62 | |||
| GAF | 46.25 ± 10.00 | |||
Data are presented as the means ± standard deviations (SD).
Abbreviations: FEP first-episode psychosis, HC healthy control, PANSS Positive and Negative Syndrome Scale, GAF Global Assessment of Functioning.
aIndependent t test or Welch’s t test if the variances were not equal, χ2 analysis or Fisher’s exact test for categorical data.
bOlanzapine-equivalent dose.